Completion of the introduction of a large-scale culture system aimed at cancer immunotherapy.

We are pleased to announce that we have completed the introduction of a single-use automated culture system for the manufacturing of clinical trial products at Helios, Inc.'s cell processing facility, in collaboration with Helios, a biotech venture developing function-enhanced NK (natural killer) cells derived from human iPS cells (gene-edited NK cells derived from human iPS cells) for large-scale culture research and development. In this initiative, Helios has successfully established a feeder-free culture system in a fully closed system for the entire process, achieving a target culture of 100 billion cells per batch. Trial operations will begin soon, aiming for early administration to patients.
For more details, please refer to the news release linked in the related links.

Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration